BPC-157 Capsules

BPC-157 Capsules contain the synthetic pentadecapeptide BPC-157 (Body Protection Compound-157) in an oral capsule formulation. BPC-157 is a 15-amino acid peptide derived from a partial sequence of human gastric juice protein, notable for its exceptional stability in acidic conditions. This gastric acid stability makes BPC-157 one of the few peptides studied for oral bioavailability, as most peptides are rapidly degraded in the digestive tract. The oral capsule format reflects the extensive body of preclinical research on BPC-157 using oral and intragastric administration routes, particularly in gastrointestinal models. BPC-157 has been investigated in over 100 preclinical studies spanning multiple organ systems, with a significant portion utilizing oral dosing. The capsule formulation is designed for research examining the peptide’s activity when administered through the gastrointestinal route.

Orally administered BPC-157 has been investigated for its direct interaction with gastrointestinal mucosal tissue and its systemic effects following absorption from the GI tract. Researchers observed that BPC-157’s stability in gastric acid allows it to maintain structural integrity through the stomach, a property attributed to its origin as a fragment of gastric juice protein. Studies suggest that oral BPC-157 interacts with the nitric oxide system, VEGF signaling, and growth factor receptor pathways in gastrointestinal tissue. In preclinical models using intragastric administration, researchers observed effects comparable to parenteral routes for gastrointestinal endpoints. The peptide has been investigated for its interactions with tight junction protein expression, mucosal blood flow regulation, and enteric nervous system signaling when delivered orally. The oral route has been the primary administration method in many of the original Croatian studies by the Sikiric laboratory.

Oral BPC-157 in GI Models

Sikiric et al. (2006) reviewed the extensive preclinical literature on oral BPC-157 administration in gastrointestinal models. The authors summarized findings from multiple studies using intragastric dosing in models of mucosal injury, inflammation, and fistula healing [1].

Acid Stability

Sikiric et al. (2010) described the pharmacological profile of BPC-157, including its notable stability in gastric acid and its activity across multiple administration routes including oral, demonstrating maintained bioactivity after passage through the acidic gastric environment [2].

Cytoprotective Mechanisms

Seiwerth et al. (2014) investigated oral BPC-157 in alcohol-induced gastric lesion models. Researchers observed that intragastric administration was associated with maintained mucosal integrity and altered expression of growth factors compared to vehicle-treated controls [3].